Literature DB >> 24958497

Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model.

Karen A Griffin1, Aaron Polichnowski2, Natalia Litbarg2, Maria Picken2, Manjeri A Venkatachalam2, Anil K Bidani2.   

Abstract

Most patients with essential hypertension do not exhibit substantial renal damage. Renal autoregulation by preventing glomerular transmission of systemic pressures has been postulated to mediate this resistance. Conversely, malignant nephrosclerosis (MN) has been postulated to develop when severe hypertension exceeds a critical ceiling. If the concept is valid, even modest blood pressure (BP) reductions to below this threshold regardless of antihypertensive class (1) should prevent MN and (2) lead to the healing of the already developed MN lesions. Both predicates were tested using BP radiotelemetry in the stroke-prone spontaneously hypertensive rats receiving 1% NaCl as drinking fluid for 4 weeks. Severe hypertension (final 2 weeks average systolic BP, >200 mm Hg) and MN (histological damage score 36±5; n=27) developed in the untreated stroke-prone spontaneously hypertensive rats but were prevented by all antihypertensive classes (enalapril [n=15], amlodipine [n=13], or a hydralazine/hydrochlorothiazide combination [n=15]) if the final 2-week systolic BP remained <190 mm Hg. More impressively, modest systolic BP reductions to 160 to 180 mm Hg (hydralazine/hydrochlorothiazide regimen) initiated at ≈4 weeks in additional untreated rats after MN had already developed (injury score 35±4 in the right kidney removed before therapy) led to a striking resolution of the vascular and glomerular MN injury over 2 to 3 weeks (post-therapy left kidney injury score 9±2, P<0.0001; n=27). Proteinuria also declined rapidly from 122±9.5 mg/24 hours before therapy to 20.5±3.6 mg 1 week later. These data clearly demonstrate the barotrauma-mediated pathogenesis of MN and the striking capacity for spontaneous and rapid repair of hypertensive kidney damage if new injury is prevented.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  calcium channel blockers; hypertension; renal circulation; renin-angiotensin system

Mesh:

Substances:

Year:  2014        PMID: 24958497      PMCID: PMC4162752          DOI: 10.1161/HYPERTENSIONAHA.114.03609

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  44 in total

1.  Management of malignant hypertension complicated by renal insufficiency. A follow-up study.

Authors:  J W Woods; W B Blythe; W D Huffines
Journal:  N Engl J Med       Date:  1974-07-04       Impact factor: 91.245

2.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Authors:  Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

3.  Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases.

Authors:  Jean-Jacques Boffa; Ying Lu; Sandrine Placier; Adam Stefanski; Jean-Claude Dussaule; Christos Chatziantoniou
Journal:  J Am Soc Nephrol       Date:  2003-05       Impact factor: 10.121

4.  Differential salt-sensitivity in the pathogenesis of renal damage in SHR and stroke prone SHR.

Authors:  K A Griffin; P C Churchill; M Picken; R C Webb; T W Kurtz; A K Bidani
Journal:  Am J Hypertens       Date:  2001-04       Impact factor: 2.689

5.  Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent.

Authors:  Karen A Griffin; Isam Abu-Amarah; Maria Picken; Anil K Bidani
Journal:  Hypertension       Date:  2003-02       Impact factor: 10.190

6.  Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats.

Authors:  Marcin Adamczak; Marie-Luise Gross; Jan Krtil; Andreas Koch; Karin Tyralla; Kerstin Amann; Eberhard Ritz
Journal:  J Am Soc Nephrol       Date:  2003-11       Impact factor: 10.121

Review 7.  Pathophysiology of hypertensive renal damage: implications for therapy.

Authors:  Anil K Bidani; Karen A Griffin
Journal:  Hypertension       Date:  2004-09-27       Impact factor: 10.190

8.  Effects of calcium channel blockers on "dynamic" and "steady-state step" renal autoregulation.

Authors:  Karen A Griffin; Rifat Hacioglu; Isam Abu-Amarah; Rodger Loutzenhiser; Geoffrey A Williamson; Anil K Bidani
Journal:  Am J Physiol Renal Physiol       Date:  2004-03-02

9.  "Step" vs. "dynamic" autoregulation: implications for susceptibility to hypertensive injury.

Authors:  Anil K Bidani; Rifat Hacioglu; Isam Abu-Amarah; Geoffrey A Williamson; Rodger Loutzenhiser; Karen A Griffin
Journal:  Am J Physiol Renal Physiol       Date:  2003-03-11

10.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

Authors:  Fiona Turnbull
Journal:  Lancet       Date:  2003-11-08       Impact factor: 79.321

View more
  13 in total

1.  Genetic Susceptibility to Hypertension-Induced Renal Injury.

Authors:  Richard J Roman; Fan Fan
Journal:  Hypertension       Date:  2018-02-05       Impact factor: 10.190

2.  Progression of Chronic Kidney Disease After Acute Kidney Injury: Role of Self-Perpetuating Versus Hemodynamic-Induced Fibrosis.

Authors:  Maria Picken; Jianrui Long; Geoffrey A Williamson; Aaron J Polichnowski
Journal:  Hypertension       Date:  2016-08-22       Impact factor: 10.190

3.  Hemodynamic basis for the limited renal injury in rats with angiotensin II-induced hypertension.

Authors:  Aaron J Polichnowski; Karen A Griffin; Maria M Picken; Hector Licea-Vargas; Jianrui Long; Geoffrey A Williamson; Anil K Bidani
Journal:  Am J Physiol Renal Physiol       Date:  2014-12-04

Review 4.  Animal Models of Hypertension: A Scientific Statement From the American Heart Association.

Authors:  Lilach O Lerman; Theodore W Kurtz; Rhian M Touyz; David H Ellison; Alejandro R Chade; Steven D Crowley; David L Mattson; John J Mullins; Jeffrey Osborn; Alfonso Eirin; Jane F Reckelhoff; Costantino Iadecola; Thomas M Coffman
Journal:  Hypertension       Date:  2019-06       Impact factor: 10.190

5.  Acute Increase of Renal Perfusion Pressure Causes Rapid Activation of mTORC1 (Mechanistic Target Of Rapamycin Complex 1) and Leukocyte Infiltration.

Authors:  Satoshi Shimada; Chun Yang; Vikash Kumar; David L Mattson; Allen W Cowley
Journal:  Hypertension       Date:  2022-03-16       Impact factor: 9.897

6.  Microvascular rarefaction and hypertension in the impaired recovery and progression of kidney disease following AKI in preexisting CKD states.

Authors:  Aaron J Polichnowski
Journal:  Am J Physiol Renal Physiol       Date:  2018-09-26

7.  BP Fluctuations and the Real-Time Dynamics of Renal Blood Flow Responses in Conscious Rats.

Authors:  Anil K Bidani; Aaron J Polichnowski; Hector Licea-Vargas; Jianrui Long; Stephanie Kliethermes; Geoffrey A Williamson; Karen A Griffin
Journal:  J Am Soc Nephrol       Date:  2019-12-02       Impact factor: 10.121

Review 8.  Hypertensive Kidney Injury and the Progression of Chronic Kidney Disease.

Authors:  Karen A Griffin
Journal:  Hypertension       Date:  2017-07-31       Impact factor: 10.190

Review 9.  From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency.

Authors:  A Cremer; F Amraoui; G Y H Lip; E Morales; S Rubin; J Segura; B J Van den Born; P Gosse
Journal:  J Hum Hypertens       Date:  2015-11-19       Impact factor: 3.012

10.  Posterior reversible encephalopathy syndrome in stroke-prone spontaneously hypertensive rats on high-salt diet.

Authors:  Fanny Herisson; Iris Zhou; Jerome Mawet; E Du; Arnavaz H Barfejani; Tao Qin; Marilyn J Cipolla; Philip Z Sun; Natalia S Rost; Cenk Ayata
Journal:  J Cereb Blood Flow Metab       Date:  2018-01-19       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.